Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 11Terminated 4Active not recruiting 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Gulf War Illness 1Breast Neoplasms 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Mifepristone × Clear all
NCT02788981 2025-06-10

Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer

University of Chicago

Phase 2 Active not recruiting
29 enrolled 11 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04254627 2025-02-19

E/M

Nova Southeastern University

Phase 1 Active not recruiting
20 enrolled

Gulf War Illness

Data powered by HemOnc (CC BY 4.0) Colophon ⚡